Roche Diagnostics and Burjeel Holdings Join Forces for Enhanced Digital Diagnostics and Patient Care
The companies will combine their expertise and technical support to develop innovative digital solutions across the entire healthcare spectrum, including precise diagnosis and personalized treatment pathways
Roche Diagnostics Middle East FZCO, a global leader in diagnostics, and Burjeel Holdings, one of the largest healthcare services providers in the MENA region, have entered into a Memorandum of Understanding (MOU) to leverage cutting-edge technology in digitizing & innovating laboratory processes. The partnership between the both companies is driven by their shared commitment to improving the patient experience and outcomes by providing accurate, reliable, and efficient services.
As “Digital Lab Incubation Partners”, both parties will combine their expertise and technical support for innovative digital solutions across the entire healthcare spectrum, including precise diagnosis and personalized treatment pathways. The collaboration will generate structured reports, use cases, and whitepapers, capturing valuable knowledge and insights acquired from these digital initiatives.
“Today, we embark on an inspiring journey with Burjeel Holdings, fueled by the shared vision of transforming healthcare through digital diagnostics. This MoU reaffirms our commitment to providing advanced solutions that empower healthcare professionals and amplify the patient experience. By integrating cutting-edge technology into laboratory operations, we aim to accelerate the diagnostic process, enabling more precise and timely interventions. This partnership aligns seamlessly with our mission to create a healthier future through innovation,” said Guido Sander, General Manager at Roche Diagnostics Middle East FZCO.
“We are thrilled to forge this strategic partnership with Roche Diagnostics, a global leader in the field. This collaboration emphasizes our dedication to offering the most advanced diagnostic solutions. Through the integration of digital diagnostics, we aim to enhance the patient journey by delivering faster, more accurate diagnoses and tailored treatment plans. This milestone showcases our commitment to excellence and innovation in healthcare,” said Mr. John Sunil CEO at Burjeel Holdings.
This partnership between Roche Diagnostics and Burjeel Holdings signifies a resolute commitment to elevating healthcare standards in the region through innovation and collaboration. Both organizations are looking forward to leverage their collective strengths to bring about positive transformations in the healthcare landscape.